ASS1 and neoplasm: This is consistent with recent work showing that ASS1-expressing CAR-T cells are more effective at targeting tumor cells in vivo (Fultang et al., 2020), suggesting a potential therapeutic strategy to rescue T cell growth in arginine-depleted patients.